Comparison of the Sensitivities of Primary Isolates of HIV Type 2 and HIV Type 1 to Antiviral Drugs and Drug Combinations
- 1 December 1994
- journal article
- research article
- Published by Mary Ann Liebert Inc in AIDS Research and Human Retroviruses
- Vol. 10 (12) , 1725-1729
- https://doi.org/10.1089/aid.1994.10.1725
Abstract
The sensitivity of primary isolates of HIV-2 to the antiretroviral drugs 3′-azido-3′-deoxythymidine (AZT), 2′,3′-dideoxyinosine (ddI), and 3′-fluoro-3′-deoxythymidine (FLT) was measured in vitro in PBMCs and compared to that of primary isolates of HIV-1. HIV-2 isolates showed a similar sensitivity to the drugs compared to HIV-1 isolates. Both the relative and the absolute potencies of the three drugs were similar for inhibition of HIV-1 or HIV-2 replication. The effect of combinations of the antiviral drugs was also studied. The combinations of AZT plus FLT, AZT plus ddI, and FLT plus ddI showed synergistic inhibition of three primary HIV-2 isolates, similar to that previously shown for primary HIV-1 isolates. These results indicate that primary isolates of HIV-2 from untreated persons show a level of sensitivity to antiviral nucleoside analogs similar to that shown by HIV-1 isolates, and are also synergistically inhibited by drug combinations shown to be synergistic against HIV-1. Therapeutic regimes with nucleoside analogs used clinically against HIV-1 infection may therefore also be similarly useful against infection with HIV-2.Keywords
This publication has 43 references indexed in Scilit:
- Lack of synergy in the inhibition of HIV-1 reverse transcriptase by combinations of the 5′-triphosphates of various anti-HIV nucleoside analogsAntiviral Research, 1993
- Convergent combination therapy can select viable multidrug-resistant HIV-1 in vitroNature, 1993
- Use of evolutionary limitations of HIV-1 multidrug resistance to optimize therapyNature, 1993
- Nucleoside Analogs: Similarities and DifferencesClinical Infectious Diseases, 1993
- Loss of Synergistic Response to Combinations Containing AZT in AZT-Resistant HIV-1AIDS Research and Human Retroviruses, 1992
- Ordered Appearance of Zidovudine Resistance Mutations during Treatment of 18 Human Immunodeficiency Virus-Positive SubjectsThe Journal of Infectious Diseases, 1992
- Zidovudine resistance predicted by direct detection of mutations in DNA from HIV-infected lymphocytesAIDS, 1991
- Replicative capacity of HIV-2, like HIV-1, correlates with severity of immunodeficiencyAIDS, 1990
- Isolation of drug-resistant variants of HIV-1 from patients on long-term zidovudine therapyAIDS, 1989
- A New Human Retrovirus Isolate of West African Origin (SBL-6669) and Its Relationship to HTLV-IV, LAV-II, and HTLV-IIIBAIDS Research and Human Retroviruses, 1987